Lingerie specialist is interim CEO at JJB
JJB Sports, the struggling sportswear retailer which shucked off its Chief Executive Officer (CEO) Keith Jones last Friday, has announced retail veteran Beverley Williams as Jones's interim replacement.
JJB Sports, the struggling sportswear retailer which shucked off its Chief Executive Officer (CEO) Keith Jones last Friday, has announced retail veteran Beverley Williams as Jones's interim replacement.
Williams, who has spent more than 25 years in senior executive positions in the retail trade, will join the business with immediate effect and work closely with Chairman-designate Bob Corliss and the management team as they seek to turn around the company's fortunes.
Williams's most recent gig was as Commercial Director and co-CEO of La Senza. Prior to joining La Senza in 2007, she was General Manager for Contessa, the lingerie retailer and oversaw its revival and integration into the La Senza business.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Commenting on the appointment, Bob Corliss said: "Beverley brings a wealth of experience in multi-channel retailing, which forms a core part of the JJB offering. She is particularly well known for her expertise in product and trading."
Reaction to the appointment has not been positive, with the shares trading down a halfpenny at the end of the lunchtime session at 5.50p.
JH
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published